Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Optimal timing for Angiotensin Converting Enzyme (ACE) Inhibitor discontinuation in patients undergoing cardiac surgery on cardiopulmonary bypass.
ISRCTN ISRCTN09881876
ClinicalTrials.gov identifier
Public title Optimal timing for Angiotensin Converting Enzyme (ACE) Inhibitor discontinuation in patients undergoing cardiac surgery on cardiopulmonary bypass.
Scientific title
Acronym N/A
Serial number at source N0436130524
Study hypothesis There is some evidence that the continuation of ACE inhibitors until the time of surgery may lead to increased requirements of vasoconstrictor agents to maintain blood pressure. We aim to investigate this suggestion.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Surgery: Cardiovascular
Participants - inclusion criteria Patients undergoing elective first time coronary artery surgery on the ACE inhibitor Ramipril will be eligible for the study.
Participants - exclusion criteria Exclusion criteria are redo procedures and poor left ventricular function (Ejection Fraction <30%).
Anticipated start date 01/06/2003
Anticipated end date 01/02/2006
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Patients will be randomised to discontinuing their ACE inhibitor 7 days preoperatively or continuing the medication until the morning of operation.
Primary outcome measure(s) Primary outcome measures are those relating to the presence and treatment of perioperative and postoperative hypotension. Systemic vascular resistance will be measured via Swan-Ganz catheterisation preoperatively and at fixed intervals in the postoperative period. In addition the requirement of vasoconstrictor agents as well as the duration of their use and the total dose administered will be documented.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Leeds Teaching Hospitals NHS Trust (UK)
Trial website
Publications
Contact name Mr  A A A  Ali
  Address Department of Cardiothoracic Surgery
Yorkshire Heart Centre
Leeds General Infirmary
Great George Street
  City/town Leeds
  Zip/Postcode LS1 3EX
  Country United Kingdom
  Tel +44 (0)7967 672729
  Fax +44 (0)113 392 5408
  Email r&d@leedsth.nhs.uk
Sponsor Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
  Address The Department of Health,
Richmond House,
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2004
Last edited 21/12/2009
Date ISRCTN assigned 30/09/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central